Suzetrigine
Based on 10 publication(s) in Google Scholar
Suzetrigine (VX-548) is an orally active and highly selective NaV1.8 inhibitor that acts as an analgesic. Suzetrigine is also a blocker of sodium channel protein type 10 subunit alpha. Suzetrigine is promising for research of acute pain after abdominoplasty and bunionectomy.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.98%
- CAS No.: 2649467-58-1
- 화학식: C21H20F5N3O4
- 분자량:473.39
-
보관:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Suzetrigine
More- J Headache Pain. 2026 Aug 10;27(1):202.
- Biomolecules. 2026 Aug;16(8):1074.
- FASEB J. 2026 Mar 31;40(6):e71706. [Abstract]
- J Gen Physiol. 2025 Jul 7;157(4):e202413719. [Abstract]
- Mol Pharmacol. 2026 May-Jun;108(5-6):100125. [Abstract]
- Biopharm Drug Dispos. 2024 Apr;45(2):107-114. [Abstract]
- bioRxiv. 2026 Sep 25.
- bioRxiv. 2026 Aug 25.
- bioRxiv. 2026 Mar 3.
- bioRxiv. 2025 April 15.
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Biological Activity
제품 설명
In Vivo
Pharmacokinetic parameters of Suzetrigine in monkey plasma after oral and intravenous administrations[3]
| Parameters | AUC0-t (ng·h/mL) | Cmax (ng/mL) | Tmax (h) | T1/2 (h) | CL (mL/min/kg) | Vd (L/kg) | MRT0-t (h) | F (%) |
| Intravenous (1 mg/kg, n = 3) | 2843.2 ± 350.2 | - | - | 4.6 ± 0.2 | 5.8 ± 0.6 | 2.3 ± 0.4 | 5.7 ± 0.2 | 71 |
| Oral (2 mg/kg, n = 3) | 4040.8 ± 212.5 | 533.3 ± 10.6 | 1 | 5.0 ± 0.9 | 7.2 ± 0.5 | 3.5 ± 0.6 | 7.6 ± 0.7 |